Management of Hepatotoxicity Induced by the Use of Olanzapine

Yunus Emre Dönmez1, Özlem Özcan1, Nusret Soylu1

  • 11 Department of Child and Adolescent Psychiatry, Inonu University , Malatya, Turkey .

Insights

This study presents a case of managing elevated liver enzymes caused by olanzapine without altering the dosage. This approach offers a novel strategy for patients experiencing drug-induced liver injury during neuropsychiatric treatment.

Area of Science:

  • Hepatology
  • Clinical Pharmacology
  • Neuropsychiatry

Background:

  • Drug-induced liver injury (DILI) is a significant clinical concern, with neuropsychiatric medications accounting for a notable percentage of cases.
  • Olanzapine, a commonly used antipsychotic, has been associated with hepatotoxicity, often necessitating dose reduction or discontinuation.
  • Current management strategies for olanzapine-induced hepatotoxicity typically involve altering the treatment regimen, potentially leading to therapeutic failure.

Purpose of the Study:

  • To report a unique case of olanzapine-induced elevated liver enzymes managed successfully without changing the drug dose or formulation.
  • To discuss the clinical implications and literature context of this alternative management approach for DILI.
  • To highlight a potentially novel strategy for managing olanzapine-associated hepatotoxicity.

Main Methods:

  • Case report detailing a patient who developed elevated liver enzymes during olanzapine treatment.
  • Clinical monitoring of liver function tests and patient's response to continued olanzapine therapy at the established dose.
  • Comprehensive literature review on olanzapine-induced hepatotoxicity and its management.

Main Results:

  • The patient exhibited elevated liver enzymes, indicative of hepatotoxicity, while on olanzapine therapy.
  • The elevated liver enzymes were successfully managed and normalized without any modification to the olanzapine dose or discontinuation of the drug.
  • This case demonstrates the feasibility of continuing olanzapine treatment in specific instances of drug-induced liver injury.

Conclusions:

  • Management of olanzapine-induced hepatotoxicity may not always require dose adjustment or drug cessation.
  • This case provides evidence for a novel, conservative management approach that preserves therapeutic continuity.
  • Further research is warranted to elucidate the mechanisms and patient selection criteria for this management strategy.

Related Concept Videos

Psychosis and Antipsychotic Drugs: Overview01:28

Psychosis and Antipsychotic Drugs: Overview

The term "psychosis" refers to a spectrum of mental disorders characterized by abnormal thoughts, perceptions, and behaviors. It can manifest as mood disorders, dementia, delirium with psychotic features, substance-induced psychosis with psychotic features, brief psychotic disorder, delusional disorder, schizoaffective disorder, and schizophrenia. Among all these disorders, schizophrenia is the most common psychotic disorder, affecting 1% of the worldwide population. Psychotic symptoms in all...
Psychosis: Goals of Pharmacotherapy01:26

Psychosis: Goals of Pharmacotherapy

Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation. For...
Mania and Antimanic Drugs: Overview01:24

Mania and Antimanic Drugs: Overview

Mania, a psychological condition characterized by elevated mood, increased energy, and reduced sleep need, is part of the bipolar disorder cycle. The exact cause of mania isn't entirely known, but it is thought to be a combination of genetic, environmental, and neurological factors. Bipolar disorder involves alternating manic and depressive episodes. Mood stabilizers like lithium, antipsychotics, and anticonvulsants help manage these episodes. Lithium carbonate is particularly effective as a...
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
Pharmaceutical Poisoning: Treatment Strategies01:26

Pharmaceutical Poisoning: Treatment Strategies

Treatment strategies for poisoning are a critical aspect of emergency medicine, focusing on preventing the absorption of toxins and enhancing their elimination. When a poisoning incident occurs, the first response is to halt exposure and decontaminate the patient, particularly through gastrointestinal (GI) methods if the poison was ingested.Gastrointestinal Decontamination Techniques:Activated charcoal is the cornerstone of GI decontamination. It works through adsorption, binding the toxin to...